About the Role
Manage the day-to-day operational execution of global clinical trials from study start-up through closeout, coordinating study activities, managing timelines and vendors, and monitoring study and site performance.
Responsibilities
- Manage day-to-day global clinical trial activities from study start-up through conduct and closeout, including timelines, milestones, enrollment, and study performance.
- Support protocol review, feasibility assessments, site selection and activation, and protocol amendment activities.
- Manage CROs, sites, and clinical vendors, including oversight of plans, deliverables, timelines, budgets, and quality.
- Oversee monitoring activities, including monitoring report review, U.S. co-monitoring, site performance, protocol deviations, data queries, and follow-up of significant issues.
- Identify operational risks and work cross-functionally to develop and implement mitigation strategies.
- Lead study team meetings and communicate study progress, risks, decisions, and action items to internal and external stakeholders.
- Ensure study conduct and TMF quality are consistent with study protocols, ICH/GCP, applicable regulatory requirements, and inspection-readiness expectations.
Requirements
- Clinical operations experience in biotechnology, pharmaceutical, or CRO environments.
- Strong project management, communication, problem-solving, and organizational skills.
- Proficiency with EDC, IRT, CTMS, and eTMF.
- Ability to work effectively in a small, fast-paced biotech environment.
Skills
- ADC clinical trial experience
- Project management
- Communication
- Problem-solving
- Organizational skills
- EDC
- IRT
- CTMS
- eTMF
Location
- San Francisco Bay Area
- South San Francisco
Work Type
- Contract
- Hybrid
- Full-time
Experience Level
- 6 to 12-month contract assignment
Salary/Compensations
- $70 per hour
About the Company
- ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives.
- ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built.
- Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
- ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action.
- A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors.
